• Publications
  • Influence
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
To elucidate the role of somatic alterations for renal cancer etiology and prognosis, we analyzed 227 sporadic renal epithelial tumors for mutations and hypermethylations in the von Hippel-LindauExpand
  • 217
  • 10
  • PDF
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled
BACKGROUND This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab andExpand
  • 42
  • 3
Post-ERCP pancreatitis: review of current preventive strategies
Purpose of review This article reviews the most recent literature with significant findings pertaining to the prevention of postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis.Expand
  • 28
  • 3
Training for advanced endoscopic procedures.
Advanced endoscopy has evolved from diagnostic ERCP to an ever-increasing array of therapeutic procedures including EUS with FNA, ablative therapies, deep enteroscopy, luminal stenting, endoscopicExpand
  • 14
  • 1
Peroral cholangioscopy facilitates targeted tissue acquisition in patients with suspected cholangiocarcinoma.
AIM Biliary strictures that are suspicious for cholangiocarcinoma (CCA) are commonly encountered in clinical practice in patients with and without primary sclerosing cholangitis (PSC). A definitiveExpand
  • 13
Primary sclerosing cholangitis and distribution of inflammatory bowel disease.
Readers are encouraged to write letters to the editor concerning articles that have been published in CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. Short, general comments are also considered, but use ofExpand
  • 4
1235PCILENGITIDE (CIL) COMBINED WITH CETUXIMAB AND PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): PHASE II RANDOMISED CERTO STUDY.
ABSTRACT Aim: CIL is a selective, competitive inhibitor of avb3 and avb5 integrins designed to attack the tumour and its microenvironment. CERTO is a multicentre, controlled, open-label phase IIExpand
  • 1
Systemic treatment of elderly patients with NSCLC: Results of a German prospective observational study.
e19052 Background: In various trials designed especially for elderly patients with NSCLC stage IIIB/IV (≥ 70 years) survival and QoL benefit from single or combination chemotherapy could beExpand
...
1
2
...